Pfizer (PFE) stock falls 6% on 2024 outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall Street rallies as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Pfizer Provides Full-Year 2024 Guidance
December 13, 2023 6:45 AM ESTFull-Year 2024 Revenue Guidance(1) Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition Anticipates Approximately $8 Billion in Revenues for Comirnaty(2) and Paxlovid Seagen Expected to Contribute Approximately $3.1 Billion of Revenues Expects Full-Year 2024 Operational(3) Revenue Growth of 8%-10% Including Seagen Contribution and Excluding Comirnaty(2) and Paxlovid Revenues, and 3%-5% Excluding Both Seagen Contribution and Comirnaty(2) and Paxlovid Revenues 2024 Adjusted(5) Diluted EPS Guidance Range of $2.05 to $2.25 Includes Expected Impact of Seagen Acquisition Enterprise-Wide Cost Realignment Program Now Expected to Deliver Annual Net Cost Savings of at Least $4.0 Billion, an... More
